tumour agnostic

Oncology

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.